Suicidal ideation and imminent risk of suicide are two conditions that are prevalent among major depressive disorder (MDD) patients. Despite the high prevalence of these conditions, currently approved treatments for MDD are unable to rapidly reduce depressive symptoms—a valuable clinical attribute for the treatment of suicide ideation and imminent risk of suicide in depressed patients. To address the need for rapidly effective treatments, physicians in the United States have started to prescribe ketamine (a fast-acting agent) as an off-label treatment for MDD patients with an imminent risk of suicide, in turn modifying the long-standing MDD treatment paradigm. The MDD market and treatment paradigm will likely be further disrupted as a result of the expected U.S. launch of the first two fast-acting antidepressants (esketamine and rapastinel) specifically developed and approved for the adjunctive treatment of MDD or for treatment-resistant MDD by 2020.

The infographic below combines DRG Epidemiology with surveyed and interviewed U.S. psychiatrists’ opinions to provide insight into the opportunities that exist for fast-acting emerging therapies in their treatment of imminent risk of suicide in MDD—an area of unmet in the highly genericized MDD market


For more information on the treatment of depression, browse our recent reports here.












DRG becomes Clarivate

View Now